Silence Therapeutics said this week that it has been issued a Japanese patent covering its core RNAi technology.

The patent, No. 4,705,370, is entitled “Further Novel Forms of Interfering RNA Molecules,” and claims siRNAs containing proprietary 2’-O-methyl structures.

“The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents … [a] success in our proactive ongoing intellectual property strategy,” Silence CEO Philips Haworth said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.